Consumer Health Cancer / Oncology

Lunit and Agilent Forge Collaboration to Develop AI-Powered Companion Diagnostics

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...

 September 23, 2025 | News

Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...

 September 17, 2025 | News

Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...

 September 17, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

 September 16, 2025 | News

Biostar Pharma Doses First Patients in Two Global Phase II/III Trials of Oral Utidelone Capsule for Gastric and Ovarian Cancers

 Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...

 September 16, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

 September 12, 2025 | News

Siemens Healthineers–YouGov Survey Reveals Fragmented Cancer Care Pathway in Southeast Asia, Underscoring Need for Integrated Solutions

YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...

 September 10, 2025 | Report

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

 September 10, 2025 | News

AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...

 September 08, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company  announced that the U.S. Food and Drug Administration (FDA) has gran...

 September 08, 2025 | News

FDA Approves Henlius and Organon’s Denosumab Biosimilars BILDYOS and BILPREVDA for All US Indications

Shanghai Henlius Biotech, Inc. and Organon  announced that the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) inject...

 September 04, 2025 | News

China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer

Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...

 September 03, 2025 | News

Lunit Secures Milestone European Deployment in Spain’s Valencian Community for AI-Powered Breast Cancer Screening

Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening Lunit , a leading provider o...

 September 03, 2025 | News

Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability

Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...

 September 01, 2025 | Company results


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close